To date, the risk factors linked to immunological nonresponsiveness are a lower nadir CD4 cell count before

therapy [6], lower pre-HAART HIV RNA levels, NVP-LDE225 molecular weight older age, male gender, hepatitis C virus (HCV) coinfection, injecting drug use (IDU), and of course poor adherence to therapy [7,8]. In addition, one study from France showed that Mycobacterium avium complex (MAC) infections also predicted immunological nonresponsiveness [9]. We reviewed the records of all HAART-naïve patients with AIDS presenting with CD4 counts of <100 cells/μL at two Infectious Diseases Units in Italy (one located in Verona in the north-east of Italy and the other in Cosenza in the south) and investigated whether opportunistic infections or cancers recorded at presentation had an effect on subsequent immune reconstitution on HAART. Fifty-three patients with these characteristics were identified in Verona and 20 in Cosenza (73 Rucaparib in total). Fifty-one patients (69%) were men. Their median age was 43 years. Thirty-two patients (43%) were men who have sex with men, 15 (20%) were injecting drug users, and the others were heterosexual. All patients who were

injecting drug users were HCV-coinfected. Twenty patients (27%) had Pneumocystis jiroveci pneumonia, nine (12%) disseminated MAC infections, eight (11%) cryptococcal meningitis, eight (11%) neurotoxoplasmosis, seven (10%) Candida spp. oesophagitis, six (8%) tuberculosis, six (8%) disseminated Cytomegalovirus infection,

four (5%) non-Hodgkin’s lymphomas, see more three (4%) Kaposi’s sarcoma, and two (3%) progressive multifocal leucoencephalopathy. The median CD4 T-cell count at the time of HAART initiation was 60.68 cells/μL and the median HIV RNA viral load was 572,633 HIV-1 RNA copies/mL. The median follow-up time was 6.5 years. Six patients were nonadherent and excluded from the analysis. After a median follow-up period of 3 years, all 67 adherent patients included in the analysis had sustained viral load suppression (HIV RNA <50 copies/mL), and the median CD4 T-cell count was 391.79 cells/μL. In the analysis of relationships with presenting opportunistic infections or cancers, a lower increase in CD4 T-cell count (median 59.75 cells/μL) and total lymphocyte count (median 74.21 cells/μL) was found only in patients who had experienced MAC infections.